Enliven insider plans 82,500-share Rule 144 sale

Enliven Therapeutics insider Joseph Lyssikatos has filed a Rule 144 notice to sell up to 82,500 shares of common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,276,275.00.

Accepted by SEC EDGAR 01/08/2026 - 04:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Enliven Therapeutics insider Joseph Lyssikatos has filed a Rule 144 notice to sell up to 82,500 shares of common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,276,275.00. The filing notes that 59,000,000 shares of this class were outstanding and that the planned sale is expected around 01/08/2026.

The shares to be sold are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. Over the prior three months, Lyssikatos sold additional Enliven Therapeutics Inc shares in three transactions: 12,500 shares on 10/20/2025 for $276,024.53, 12,500 shares on 11/19/2025 for $279,155.45, and 5,000 shares on 12/19/2025 for $84,206.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Enliven Therapeutics (ELVN) Form 144 filing show?

The Form 144 shows that Joseph Lyssikatos plans to sell up to 82,500 shares of Enliven Therapeutics common stock on Nasdaq through Jefferies LLC, with an aggregate market value of $1,276,275.00.

How many Enliven Therapeutics (ELVN) shares are planned for sale under this Form 144?

The notice covers a proposed sale of 82,500 shares of common stock, to be sold on Nasdaq using broker Jefferies LLC.

When were the Enliven Therapeutics (ELVN) shares in this Form 144 acquired?

The shares covered by the notice are described as founder shares acquired from Enliven Therapeutics on 09/01/2019.

What recent Enliven Therapeutics (ELVN) share sales by this insider are disclosed?

Over the past three months, the filing lists three sales by Joseph Lyssikatos: 12,500 shares on 10/20/2025 for $276,024.53, 12,500 shares on 11/19/2025 for $279,155.45, and 5,000 shares on 12/19/2025 for $84,206.00.

How many Enliven Therapeutics (ELVN) shares are outstanding in the class being sold?

The filing states that there are 59,000,000 shares of the common stock class outstanding.

On which exchange will the Enliven Therapeutics (ELVN) Form 144 shares be sold?

The Form 144 indicates the Nasdaq as the exchange for the planned sale of the 82,500 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001967150
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Lyssikatos Joseph P
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	82500	1276275.00	59000000	01/08/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder shares	Enliven Therapeutics			82500	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	10/20/2025	12500	276024.53
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	11/19/2025	12500	279155.45
Joseph Lyssikatos 6200 Lookout Rd 1st Fl Boulder CO 80301	Enliven Therapeutics Inc	12/19/2025	5000	84206.00

144: Remarks and Signature

Remarks	All sales are to be made pursuant to a previously signed/adopted 10b5-1 selling plan dated 11/15/2024, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from The Lyssikatos Revocable Trust UAD 12/15/11.
Date of Notice	01/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joseph Lyssikatos
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)